Download PDF
Thromb Haemost 2012; 108(03): 476-484
DOI: 10.1160/TH12-02-0093
Review Article
Schattauer GmbH

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation

Simon Mantha
1   Department of Medicine, Lahey Clinic, Burlington, Massachusetts, USA
,
Jack Ansell
2   Department of Medicine, Lenox Hill Hospital, New York, New York, USA
› Author Affiliations
Further Information

Publication History

Received: 16 February 2012

Accepted after major revision: 07 May 2012

Publication Date:
25 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation. Two agents are direct factor Xa inhibitors (rivaroxaban and apixaban), and the third is a direct thrombin inhibitor (dabigatran). They have been separately compared to warfarin in large randomised trials. Our objective was to indirectly compare the three agents to each other for major efficacy and safety outcomes. Studies were assessed for comparability and the odds ratios of selected outcomes for each anticoagulant versus one another were estimated indirectly. The three cohorts differed significantly in terms of CHADS2 score and the number of individuals with a past history of stroke, transient ischemic attack or systemic embolism. The estimated odds ratio of stroke or systemic embolism was 1.35 for rivaroxaban vs dabigatran 150 mg (p=0.04), 0.97 for rivaroxaban versus dabigatran 110 mg (p=0.81), 1.22 for apixaban versus dabigatran 150 mg (p=0.18), 0.88 for apixaban versus dabigatran 110 mg (p=0.34) and 0.90 for apixaban versus rivaroxaban (p=0.43). The estimated odds ratio of major bleeding was 1.10 for rivaroxaban versus dabigatran 150 mg (p=0.36), 1.28 for rivaroxaban versus dabigatran 110 mg (p=0.02), 0.74 for apixaban versus dabigatran 150 mg (p=0.004), 0.87 for apixaban versus dabigatran 110 mg (p=0.17) and 0.68 for apixaban versus rivaroxaban (p<0.001). In conclusion, the available data indicate no significant difference in efficacy between dabigatran 150 mg and apixaban for the prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation. It appears however that apixaban is associated with less major bleeding than dabigatran 150 mg or rivaroxaban and that rivaroxaban is less effective than dabigatran 150 mg in preventing stroke or systemic embolism. Such an indirect comparison should be used only to generate hypotheses which need to be tested in a dedicated randomised trial comparing the three drugs directly.

Keywords

Atrial fibrillation - anticoagulants - stroke
 

  • References

  • 1 Go AS, Hylek EM, Phillips KA. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
    CrossrefPubMedSearch in Google Scholar
  • 2 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
    CrossrefPubMedSearch in Google Scholar
  • 3 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
    CrossrefPubMedSearch in Google Scholar
  • 4 Rosand J, Eckman MH, Knudsen KA. et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880-884.
    CrossrefPubMedSearch in Google Scholar
  • 5 Holbrook AM, Pereira JA, Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-1106.
    CrossrefPubMedSearch in Google Scholar
  • 6 Albers GW, Yim JM, Belew KM. et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156: 2311-2316.
    CrossrefPubMedSearch in Google Scholar
  • 7 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedSearch in Google Scholar
  • 8 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
    CrossrefPubMedSearch in Google Scholar
  • 9 Freeman JV, Zhu R P, Owens DK. et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
    CrossrefPubMedSearch in Google Scholar
  • 10 Sorensen SV, Kansal AR, Connolly S. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation:A Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
    CrossrefPubMedSearch in Google Scholar
  • 12 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
    CrossrefPubMedSearch in Google Scholar
  • 13 Stangier J, Rathgen K, Stahle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
    CrossrefPubMedSearch in Google Scholar
  • 14 Mueck W, Becka M, Kubitza D. et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-344.
    CrossrefPubMedSearch in Google Scholar
  • 15 He K, Luettgen JM, Zhang D. et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet 2011; 36: 129-139.
    CrossrefPubMedSearch in Google Scholar
  • 16 Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 01) 9S-16S.
    CrossrefPubMedSearch in Google Scholar
  • 17 Laux V, Perzborn E, Kubitza D. et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007; 33: 515-523.
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31: 478-492.
    CrossrefPubMedSearch in Google Scholar
  • 19 Huisman MV, Lip GYH, Diener HC. et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Pengo V, Crippa L, Falanga A. et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2011; 106: 868-876.
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Goldhaber SZ. What’s the “go to” anticoagulant for stroke prevention in atrial fibrillation?. Thromb Haemost 2012; 107: 397-398.
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
    Thieme ConnectPubMedSearch in Google Scholar
  • 23 Ezekowitz MD, Connolly S, Parekh A. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810.
    CrossrefPubMedSearch in Google Scholar
  • 24 Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010 159. 340-347.
    PubMedSearch in Google Scholar
  • 25 Lopes RD, Alexander JH, Al-Khatib SM. et al. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 2010; 159: 331-339.
    CrossrefPubMedSearch in Google Scholar
  • 26 Wallentin L, Yusuf S, Ezekowitz MD. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
    CrossrefPubMedSearch in Google Scholar
  • 27 Glenny AM, Altman DG, Song F. et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 09: 1-134 iii-iv.
    PubMedSearch in Google Scholar
  • 28 Altman DG, Bland JM. Interaction revisited: the difference between two estimates. Br Med J 2003; 326: 219.
    CrossrefPubMedSearch in Google Scholar
  • 29 Bland JM, Altman DG. Statistics notes. The odds ratio. Br Med J 2000; 320: 1468.
    PubMedSearch in Google Scholar
  • 30 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
    CrossrefPubMedSearch in Google Scholar
  • 31 Poli D, Antonucci E, Marcucci R. et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 2007; 121: 347-352.
    CrossrefPubMedSearch in Google Scholar
  • 32 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
    CrossrefPubMedSearch in Google Scholar
  • 33 Shireman TI, Howard PA, Kresowik TF. et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35: 2362-2367.
    CrossrefPubMedSearch in Google Scholar
  • 34 Ezekowitz MD, Wallentin L, Connolly SJ. et al. Dabigatran and Warfarin in Vitamin K Antagonist-Naive and -Experienced Cohorts With Atrial Fibrillation. Circulation 2010; 122: 2246-2253.
    CrossrefPubMedSearch in Google Scholar
  • 35 Mega JL, Braunwald E, Wiviott SD. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
    CrossrefPubMedSearch in Google Scholar
  • 36 Fadda V, Maratea D, Trippoli S. et al. Network meta-analysis. Results can be summarised in a simple figure. Br Med J 2011; 342: d1555.
    CrossrefPubMedSearch in Google Scholar